MedWatch

Ferring in Denmark to launch newly-purchased cancer treatment in Europe

The pharmaceutical company Ferring has purchased rights to a phase-3 cancer treatment, which Ferring's Danish department will be working with in Europe. However, the acquisition does not mean that Ferring will become a cancer-focused firm, says Ferring's CEO in Denmark.

Ferring's department in Ørestad, Copenhagen in Denmark. | Foto: Martin Havtorn Petersen/MedWatch

The Swiss-based pharmaceutical company Ferring has purchased rights to sell a gene therapy named Rad-IFN/Syn3 used for treating bladder neoplasm, which is presently in phase-3 testing at the Finnish biotech firm FKD Therapies.

The purchase will provide the company's Danish department, which has around 500 employees, with new tasks in delivering this new hope in the fight against cancer to the European market.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Coloplasts nye skattedetaljer viser enorme nationale forskelle - Danmark blandt de laveste skatteopkrævere

Mens Coloplast betaler godt 20 pct. i effektiv skattesats herhjemme, lægger medicoselskabet næsten 40 pct. i skatteposen af sit overskud i Frankrig, viser nye detaljerede skatteoplysninger fra virksomheden. Størstedelen af medicoselskabets ansatte arbejder i Ungarn, hvor firmaet også betaler den laveste selskabsskat på bare 15 pct, men produktionen er lagt i landet af en række andre årsager, fortæller Coloplast.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier